The startup develops a biotechnology platform that precisely regulates cell death by targeting ferroptosis, a process that can lead to cell death in various diseases. Their therapeutics aim to inhibit or promote ferroptosis, providing patients with effective treatment options to manage conditions associated with abnormal cell death.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, such as cancer and neurodegenerative disorders, are characterized by dysregulation of cell death pathways. Current therapeutic strategies often lack the precision to selectively target and modulate specific cell death mechanisms, leading to off-target effects and limited efficacy.
Solution
This startup is developing a biotechnology platform focused on precisely controlling cell death through the modulation of ferroptosis, an iron-dependent form of regulated necrosis. Their therapeutic approach involves developing molecules that either inhibit or promote ferroptosis, depending on the disease context. By targeting this specific cell death pathway, they aim to create more effective and targeted treatments for diseases associated with either excessive or insufficient ferroptosis. This precision approach has the potential to minimize off-target effects and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from cancers, neurodegenerative diseases, and other conditions where modulation of cell death pathways can provide therapeutic benefit.
Features
- Development of small molecule inhibitors of ferroptosis for diseases characterized by excessive cell death.
- Development of small molecule inducers of ferroptosis for diseases where increased cell death is desired, such as cancer.
- Target identification and validation using cell-based assays and in vivo models.
- Proprietary screening platform for identifying novel ferroptosis modulators.